Geode Capital Management’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $17.7M | Buy |
|
|||||
|
2025
Q1 | $16.1M | Buy |
|
|||||
|
2024
Q4 | $17.2M | Buy |
|
|||||
|
2024
Q3 | $19.2M | Buy |
|
|||||
|
2024
Q2 | $15.9M | Buy |
|
|||||
|
2024
Q1 | $8.36M | Buy |
|
|||||
|
2023
Q4 | $6.43M | Buy |
|
|||||
|
2023
Q3 | $5.92M | Buy |
|
|||||
|
2023
Q2 | $8.46M | Buy |
|
|||||
|
2023
Q1 | $775K | Buy |
|
|||||
|
2022
Q4 | $563K | Buy |
|
|||||
|
2022
Q3 | $239K | Buy |
|
|||||
|
2022
Q2 | $68K | Buy |
|
|||||
|
2022
Q1 | $102K | Sell |
|
|||||
|
2021
Q4 | $123K | Hold |
|
|||||
|
2021
Q3 | $223K | Buy |
|
|||||
|
2021
Q2 | $406K | Sell |
|
|||||
|
2021
Q1 | $885K | Buy |
|
|||||
|
2020
Q4 | $2.25M | Buy |
|
|||||
|
2020
Q3 | $1.69M | Buy |
|
|||||
|
2020
Q2 | $2.27M | Buy |
|